Acousia
is a Germany-based clinical-stage biotech company that researches and develops novel therapeutics for the treatment of acute and chronic diseases... Read moreAcousia
is a Germany-based clinical-stage biotech company that researches and develops novel therapeutics for the treatment of acute and chronic diseases... Read more
News
Jan 08, 2026
Business Mole
Acousia: ACOU085 (INN: Bimokalner) Completes Patient Enrollment in Phase 2 PROHEAR Study for Preventing Cisplatin-Induced Ototoxicity, Says Acousia
Apr 29, 2025
FinanzNachrichten
Acousia: Acousia Therapeutics GmbH: Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Aug 12, 2024
FinanzNachrichten
Acousia: Acousia Therapeutics GmbH: Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences
Feb 15, 2024
FinanzNachrichten
Acousia: Acousia Therapeutics GmbH: Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Jan 10, 2024
FinSMEs
Acousia Therapeutics: Acousia Therapeutics Receives Investment from Esperante Ventures
Jan 09, 2024
FinanzNachrichten
Acousia Therapeutics: Acousia Therapeutics GmbH: Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Oct 10, 2023
Post Online Media
Acousia Therapeutics: Hearing loss company Acousia Therapeutics green lighted for Phase 2 trial
Aug 23, 2023
FinanzNachrichten
Acousia Therapeutics: Acousia Therapeutics GmbH: Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Dec 13, 2022
Post Online Media
Acousia Therapeutics: Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Nov 24, 2022
Markets Insider
Acousia Therapeutics: Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11-15
Acousia Competitors
1
2
3
4
5
6
7
8
9
10